X Bioscience Public Company Limited
X Bioscience Public Company Limited, together with its subsidiaries, sells food and beverages in Thailand. It engages in the food and beverages investment and restaurant businesses. The company also manufactures and sells biological products; and generates and transmits electric power. Its brands include Kagonoya, Le Boeuf, and Bake Cheese Tart. The company was formerly known as Wow Factor Public… Read more
X Bioscience Public Company Limited (XBIO) - Total Assets
Latest total assets as of September 2024: ฿808.02 Million THB
Based on the latest financial reports, X Bioscience Public Company Limited (XBIO) holds total assets worth ฿808.02 Million THB as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
X Bioscience Public Company Limited - Total Assets Trend (2020–2023)
This chart illustrates how X Bioscience Public Company Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
X Bioscience Public Company Limited - Asset Composition Analysis
Current Asset Composition (December 2023)
X Bioscience Public Company Limited's total assets of ฿808.02 Million consist of 9.6% current assets and 90.4% non-current assets.
| Asset Category | Amount (THB) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ฿0.00 | 3.6% |
| Accounts Receivable | ฿587.00K | 0.1% |
| Inventory | ฿6.76 Million | 0.9% |
| Property, Plant & Equipment | ฿0.00 | 0.0% |
| Intangible Assets | ฿146.54 Million | 19.8% |
| Goodwill | ฿246.18 Million | 33.3% |
Asset Composition Trend (2020–2023)
This chart illustrates how X Bioscience Public Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: X Bioscience Public Company Limited's current assets represent 9.6% of total assets in 2023, an increase from 7.0% in 2020.
- Cash Position: Cash and equivalents constituted 3.6% of total assets in 2023, up from 3.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, a decrease from 72.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 33.3% of total assets.
X Bioscience Public Company Limited Competitors by Total Assets
Key competitors of X Bioscience Public Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen Agricultural Products Co Ltd
SHE:000061
|
China | CN¥23.90 Billion |
|
Maiquer Group Co Ltd
SHE:002719
|
China | CN¥1.09 Billion |
|
Jinzi Ham Co Ltd
SHE:002515
|
China | CN¥2.67 Billion |
|
Dongwon Ind
KO:006040
|
Korea | ₩7.56 Trillion |
|
SCC Holdings Bhd
KLSE:0158
|
Malaysia | RM55.24 Million |
|
Kim Teck Cheong Consolidated Bhd
KLSE:0180
|
Malaysia | RM522.43 Million |
|
Dongsuh
KO:026960
|
Korea | ₩1.77 Trillion |
|
Wellspire Holdings Berhad
KLSE:0271
|
Malaysia | RM68.85 Million |
X Bioscience Public Company Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - X Bioscience Public Company Limited generates 0.42x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - X Bioscience Public Company Limited is currently not profitable relative to its asset base.
X Bioscience Public Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.29 | 0.14 | 0.14 |
| Quick Ratio | 0.27 | 0.12 | 0.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ฿-276.99 Million | ฿ -326.80 Million | ฿ -326.80 Million |
X Bioscience Public Company Limited - Advanced Valuation Insights
This section examines the relationship between X Bioscience Public Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.40 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.6% |
| Total Assets | ฿739.39 Million |
| Market Capitalization | $430.24K USD |
Valuation Analysis
Below Book Valuation: The market values X Bioscience Public Company Limited's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: X Bioscience Public Company Limited's assets grew by 5.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for X Bioscience Public Company Limited (2020–2023)
The table below shows the annual total assets of X Bioscience Public Company Limited from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | ฿739.39 Million | +5.61% |
| 2022-12-31 | ฿700.09 Million | -46.99% |
| 2021-12-31 | ฿1.32 Billion | +3.13% |
| 2020-12-31 | ฿1.28 Billion | -- |